Results 141 to 150 of about 3,595 (167)
Some of the next articles are maybe not open access.
Infectious Diseases
Background Dalbavancin is a long-acting lipoglycopeptide approved for acute bacterial skin and soft-tissue infections. Its prolonged half-life enables outpatient treatment, reducing the burden of hospitalisation.
A. Hall, E. Månsson, Anders Krifors
semanticscholar +1 more source
Background Dalbavancin is a long-acting lipoglycopeptide approved for acute bacterial skin and soft-tissue infections. Its prolonged half-life enables outpatient treatment, reducing the burden of hospitalisation.
A. Hall, E. Månsson, Anders Krifors
semanticscholar +1 more source
Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada
Introduction Treatment of acute bacterial skin and skin structure infections (ABSSSIs) with intravenous (IV) antibiotics is difficult in marginalized populations, such as people who inject drugs, due to issues such as unstable housing or mental health ...
W. Leung +10 more
semanticscholar +1 more source
Introduction Treatment of acute bacterial skin and skin structure infections (ABSSSIs) with intravenous (IV) antibiotics is difficult in marginalized populations, such as people who inject drugs, due to issues such as unstable housing or mental health ...
W. Leung +10 more
semanticscholar +1 more source
Drugs of Today, 2007
Dalbavancin is a second-generation lipoglycopeptide bactericidal agent. Due to its once-weekly intravenous (i.v.) dosing and greater tissue penetration, dalbavancin may offer advantages in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) as compared to vancomycin, the gold standard in the treatment of MRSA.
openaire +2 more sources
Dalbavancin is a second-generation lipoglycopeptide bactericidal agent. Due to its once-weekly intravenous (i.v.) dosing and greater tissue penetration, dalbavancin may offer advantages in the treatment of methicillin-resistant Staphylococcus aureus (MRSA) as compared to vancomycin, the gold standard in the treatment of MRSA.
openaire +2 more sources
Journal of Antimicrobial Chemotherapy
BACKGROUND There are limited in vitro synergistic studies on dalbavancin against enterococci. We aimed to assess the in vitro activity of dalbavancin against Enterococcus faecalis strains, and to explore the interaction between dalbavancin and β-lactams.
David Luque Paz +8 more
semanticscholar +1 more source
BACKGROUND There are limited in vitro synergistic studies on dalbavancin against enterococci. We aimed to assess the in vitro activity of dalbavancin against Enterococcus faecalis strains, and to explore the interaction between dalbavancin and β-lactams.
David Luque Paz +8 more
semanticscholar +1 more source
Therapeutic Drug Monitoring
INTRODUCTION Extracorporeal membrane oxygenation (ECMO) is a life-saving support for patients with severe respiratory or cardiac failure. During ECMO support, the pharmacokinetics of drugs is often affected.
A. Cafaro +9 more
semanticscholar +1 more source
INTRODUCTION Extracorporeal membrane oxygenation (ECMO) is a life-saving support for patients with severe respiratory or cardiac failure. During ECMO support, the pharmacokinetics of drugs is often affected.
A. Cafaro +9 more
semanticscholar +1 more source
The Annals of Pharmacotherapy
BACKGROUND Dalbavancin's pharmacokinetic parameters suggest obesity may affect serum and tissue concentrations, but currently there is no outcome data in the obese population with invasive infections. OBJECTIVE The purpose of this study is to determine
Lisa Avery +3 more
semanticscholar +1 more source
BACKGROUND Dalbavancin's pharmacokinetic parameters suggest obesity may affect serum and tissue concentrations, but currently there is no outcome data in the obese population with invasive infections. OBJECTIVE The purpose of this study is to determine
Lisa Avery +3 more
semanticscholar +1 more source
Journal of the Association of Medical Microbiology and Infectious Disease Canada
Dalbavancin is approved in Canada for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). We present a single-center quality improvement case series of dalbavancin use in serious bacterial infections in people who use drugs
Adrianna N Gunton +4 more
semanticscholar +1 more source
Dalbavancin is approved in Canada for the treatment of acute bacterial skin and skin structure infections (ABSSSIs). We present a single-center quality improvement case series of dalbavancin use in serious bacterial infections in people who use drugs
Adrianna N Gunton +4 more
semanticscholar +1 more source
Dalbavancin: an investigational glycopeptide
Expert Review of Anti-infective Therapy, 2004Glycopeptide antimicrobials have been a component of our therapeutic armamentarium for nearly 50 years. Although vancomycin, and more recently teicoplanin, have performed yeoman service over the years, the specter of bacterial resistance among Gram-positive aerobes has created doubts concerning how long they will continue to be useful antimicrobial ...
openaire +2 more sources